Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 3Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 3Head & Neck 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 1131Triple Negative Breast Neoplasms 147Neoplasm Metastasis 99Carcinoma, Non-Small-Cell Lung 85Ovarian Neoplasms 81Neoplasms 75Lung Neoplasms 64Colorectal Neoplasms 60Melanoma 59Stomach Neoplasms 44Pancreatic Neoplasms 43Breast Neoplasms, Male 43Prostatic Neoplasms 42Carcinoma, Renal Cell 37Squamous Cell Carcinoma of Head and Neck 34Sarcoma 30Colonic Neoplasms 29Endometrial Neoplasms 28Head and Neck Neoplasms 26Brain Neoplasms 24Urinary Bladder Neoplasms 22Esophageal Neoplasms 21Carcinoma, Ovarian Epithelial 21Carcinoma, Intraductal, Noninfiltrating 21Lymphoma, Non-Hodgkin 19Recurrence 18Uterine Cervical Neoplasms 17Inflammatory Breast Neoplasms 17Breast Carcinoma In Situ 17Multiple Myeloma 16

Interventions

pembrolizumab 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Adenoid Cystic × Breast × Clear all
NCT05194072 2026-01-09

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Seagen Inc.

Phase 1 Terminated
250 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03422679 2024-01-16

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Cellestia Biotech AG

Phase 1/2 Terminated
79 enrolled 22 charts
BreastGastrointestinalLymphoidOther hematologic neoplasmSarcoma

Breast Neoplasms, Carcinoma, Adenoid Cystic, Glomus Tumor, Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Osteosarcoma, Colorectal Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03680560 2020-03-31

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Cogent Biosciences, Inc.

Phase 1 Terminated
6 enrolled
BreastGastrointestinal

Breast Neoplasms, Carcinoma, Adenoid Cystic, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡